Biotoscana Investments SA (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced its financial results for 2018 on Friday.
The company reported an increase in net revenue for 2018 of 10% in constant currency, positively impacted by its Dosa drug, marking BRL821m.
The firm posted net income at BRL63m in 2018 compared with BRL17m in 2017.
Gross profit increased by 12% vs 2017, in constant currency.
Gross margin of 51% (including hyperinflation adjustments) vs 54% in 2017.
OPEX are in line with 34% of net revenues in 2018.
(1USD=4BRL)
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli